Importance_NN of_IN the_DT Fourth_JJ Alpha-Helix_NN within_IN the_DT CAP_NP Homology_NP Domain_NP of_IN Type_NP II_NP Topoisomerase_NP for_IN DNA_NP Cleavage_NP Site_NP Recognition_NP and_CC Quinolone_NP Action_NP We_PP report_VBP that_IN point_NN mutations_NNS causing_VBG alteration_NN of_IN the_DT fourth_JJ alpha-helix_NN (_( alpha4-helix_NN )_) of_IN the_DT CAP_NP homology_NN domain_NN of_IN eukaryotic_JJ (_( Saccharomyces_NP cerevisiae_NNS )_) type_VBP II_NP topoisomerases_NNS (_( Ser740Trp_NP ,_, Gln743Pro_NP ,_, and_CC Thr744Pro_NP )_) change_VB the_DT selection_NN of_IN type_NN II_NP topoisomerase-mediated_JJ DNA_NN cleavage_NN sites_NNS promoted_VBN by_IN Ca2+_NP or_CC produced_VBN by_IN etoposide_NP ,_, the_DT fluoroquinolone_NP CP-115,953_NP ,_, or_CC mitoxantrone_NN ._SENT By_IN contrast_NN ,_, Thr744Ala_NP substitution_NN had_VBD minimal_JJ effect_NN on_IN Ca2+-_NP and_CC drug-stimulated_JJ DNA_NN cleavage_NN sites_NNS ,_, indicating_VBG the_DT selectivity_NN of_IN single_JJ amino_NN acid_NN substitutions_NNS within_IN the_DT alpha4-helix_NN on_IN type_NN II_NP topoisomerase-mediated_JJ DNA_NN cleavage_NN ._SENT The_DT equivalent_JJ mutation_NN in_IN the_DT gene_NN for_IN Escherichia_NP coli_NNS gyrase_NN causing_VBG Ser83Trp_NP also_RB changed_VBD the_DT DNA_NP cleavage_NN pattern_NN generated_VBN by_IN Ca2+_NP or_CC quinolones_NNS ._SENT Finally_RB ,_, Thr744Pro_NP substitution_NN in_IN the_DT yeast_NN type_NN II_NP topoisomerase_NN rendered_VBD the_DT enzyme_NN sensitive_JJ to_TO antibacterial_NN quinolones_NNS ._SENT This_DT study_NN shows_VBZ that_IN the_DT alpha4-helix_NN within_IN the_DT conserved_VBN CAP_NN homology_NN domain_NN of_IN type_NN II_CD topoisomerases_NNS is_VBZ critical_JJ for_IN selecting_VBG the_DT sites_NNS of_IN DNA_NN cleavage_NN ._SENT It_PP also_RB demonstrates_VBZ that_IN selective_JJ amino_NN acid_NN residues_NNS in_IN the_DT alpha4-helix_NN are_VBP important_JJ in_IN determining_VBG the_DT activity_NN and_CC possibly_RB the_DT binding_NN of_IN quinolones_NNS to_TO the_DT topoisomerase_JJ II-DNA_NP complexes_NNS ._SENT DNA_NP topoisomerases_NNS are_VBP enzymes_NNS that_WDT catalyze_VBP changes_NNS in_IN the_DT topology_NN of_IN DNA_NN via_IN a_DT mechanism_NN involving_VBG the_DT transient_JJ breakage_NN and_CC rejoining_VBG of_IN phosphodiester_NN bonds_NNS in_IN the_DT DNA_NP backbone_NN ._SENT Studies_NNS in_IN both_DT prokaryotic_JJ and_CC eukaryotic_JJ cells_NNS have_VBP demonstrated_VBN the_DT importance_NN of_IN topoisomerases_NNS in_IN transcription_NN ,_, DNA_NN replication_NN ,_, and_CC chromosome_NN segregation_NN ._SENT Type_NN II_CD topoisomerases_NNS (_( Top2p_NP )_) are_VBP conserved_VBN among_IN eukaryotes_NNS ._SENT Gyrase_NP and_CC topoisomerase_NP IV_NP are_VBP bacterial_JJ Top2_JJ enzymes_NNS with_IN significant_JJ sequence_NN similarity_NN to_TO eukaryotic_JJ Top2_NP proteins_NNS ._SENT Eukaryotic_NP Top2_NP enzymes_NNS are_VBP homodimeric_JJ and_CC cleave_VB one_CD DNA_NN duplex_NN (_( the_DT G_NN ,_, or_CC gate_NN ,_, segment_NN )_) using_VBG two_CD tyrosine_NN residues_NNS (_( one_CD from_IN each_DT Top2p_NP monomer_NN )_) to_TO attack_VB phosphodiester_NN bonds_NNS on_IN both_DT DNA_NN strands_NNS ._SENT In_IN this_DT process_NN ,_, each_DT enzyme_NN monomer_NN becomes_VBZ covalently_RB attached_VBN to_TO the_DT 5_CD '_POS end_NN of_IN the_DT cleaved_VBN DNA_NN by_IN a_DT phosphotyrosine_NN linkage_NN ._SENT Top2p_NP then_RB opens_VBZ the_DT DNA_NN ,_, bridging_VBG the_DT gap_NN in_IN the_DT G_NP segment_NN ._SENT A_DT second_JJ DNA_NN duplex_NN (_( the_DT T_NN ,_, or_CC transported_VBD ,_, segment_NN )_) passes_VBZ through_IN the_DT gap_NN ._SENT Thereafter_RB ,_, the_DT G_NP segment_NN is_VBZ resealed_VBN ,_, and_CC the_DT T_NN segment_NN is_VBZ liberated_VBN from_IN the_DT enzyme_NN ._SENT Under_IN physiological_JJ conditions_NNS ,_, the_DT covalent_JJ Top2p-DNA_NP complexes_NNS (_( referred_VBN to_TO as_IN cleavage_NN complexes_NNS )_) are_VBP normally_RB short-lived_JJ intermediates_NNS in_IN the_DT catalytic_JJ cycle_NN of_IN the_DT enzyme_NN ._SENT Top2p_NP requires_VBZ the_DT presence_NN of_IN a_DT divalent_JJ cation_NN for_IN catalytic_JJ activity_NN ,_, which_WDT is_VBZ Mg2+_JJ under_IN physiological_JJ conditions_NNS ._SENT However_RB ,_, when_WRB magnesium_NN is_VBZ replaced_VBN by_IN Ca2+_NP ,_, a_DT higher_JJR level_NN of_IN Top2p_NP is_VBZ trapped_VBN in_IN a_DT Ca2+-promoted_JJ covalent_JJ enzyme-DNA_NN complex_NN ,_, and_CC DNA_NN double-_NN and_CC single-stranded_JJ DNA_NN cleavage_NN can_MD be_VB detected_VBN ._SENT Beyond_IN its_PP$ vital_JJ cellular_JJ functions_NNS ,_, Top2p_NP is_VBZ the_DT primary_JJ cytotoxic_JJ target_NN for_IN some_DT of_IN the_DT most_RBS active_JJ drugs_NNS used_VBN for_IN the_DT treatment_NN of_IN human_JJ cancers_NNS (_( see_VB below_IN )_) ._SENT In_IN addition_NN ,_, inhibitors_NNS of_IN bacterial_JJ type_NN II_NP topoisomerases_NNS ,_, such_JJ as_IN quinolones_NNS ,_, are_VBP among_IN the_DT most_RBS widely_RB prescribed_VBN antibacterial_NN drugs_NNS ._SENT Top2p_NN inhibitors_NNS can_MD be_VB divided_VBN in_IN two_CD groups_NNS :_: Top2p_JJ catalytic_JJ inhibitors_NNS and_CC Top2p_NN poisons_NNS ._SENT Top2p_JJ catalytic_JJ inhibitors_NNS (_( "_`` suppressors_NNS "_'' )_) are_VBP defined_VBN as_IN drugs_NNS that_WDT inhibit_VBP enzyme_NN activity_NN but_CC do_VBP not_RB stabilize_VB DNA_NN cleavage_NN complexes_NNS ._SENT Proflavine_NP and_CC 9-aminoacridine_NP belong_VBP to_TO this_DT category_NN ._SENT Top2p_NN poisons_NNS inhibit_VBP the_DT enzyme_NN by_IN increasing_VBG the_DT steady-state_NN levels_NNS of_IN DNA_NN cleavage_NN complexes_NNS ._SENT Hence_RB ,_, they_PP convert_VBP Top2p_NP into_IN a_DT physiological_JJ toxin_NN that_WDT creates_VBZ protein-linked_JJ DNA_NN breaks_NNS in_IN the_DT genome_NN of_IN treated_VBN cells_NNS ._SENT Top2p_NN poisons_NNS can_MD ,_, in_IN turn_NN ,_, be_VB subdivided_VBN in_IN two_CD groups_NNS :_: DNA_NN intercalators_NNS --_: -which_NNS include_VBP doxorubicin_NN ,_, mitoxantrone_NN ,_, amsacrine_NN ,_, and_CC ellipticines_NNS --_: -and_NN nonintercalators_NNS ,_, whose_WP$ main_JJ representatives_NNS are_VBP the_DT demethylepipodophyllotoxins_NNS etoposide_NP (_( VP-16_NP )_) ,_, teniposide_NN (_( VM-26_NP )_) ,_, and_CC the_DT quinolones_NNS ,_, such_JJ as_IN ciprofloxacin_NN and_CC norfloxacin_NN ,_, which_WDT are_VBP specific_JJ for_IN bacterial_JJ Top2_JJ enzymes_NNS ._SENT Previous_JJ studies_NNS showed_VBD that_DT substitution_NN of_IN Gly747_JJ to_TO Glu_NP of_IN Saccharomyces_NP cerevisiae_NNS Top2p_NP and_CC B_NP show_VBP enzyme-specific_JJ differences_NNS ._SENT Cleavage_NN was_VBD reduced_VBN at_IN several_JJ sites_NNS for_IN Top2pS740W_NP and_CC Top2pQ743P_NP compared_VBN to_TO Top2pWT_NP ._SENT For_IN example_NN ,_, cleavage_NN at_IN positions_NNS 3124_CD ,_, 3147_CD ,_, 3156_CD ,_, 3226_CD ,_, 2706_CD or_CC 2707_CD ,_, 2735_CD ,_, 2741_CD ,_, 2745_CD ,_, and_CC 2754_CD was_VBD reduced_VBN for_IN Top2pS740W_NP and_CC at_IN that_IN at_IN positions_NNS 3094_CD ,_, 3170_CD ,_, 2754_CD ,_, and_CC 2735_CD was_VBD reduced_VBN for_IN Top2pQ743P_NP ._SENT Most_JJS reduction_NN in_IN Ca2+-promoted_JJ cleavage_NN was_VBD seen_VBN for_IN Top2pT744P_NP ,_, which_WDT is_VBZ in_IN contrast_NN to_TO the_DT intensity_NN of_IN the_DT drug-induced_JJ cleavage_NN sites_NNS generated_VBN by_IN Top2pT744P_NP ._SENT Cleavage_NN was_VBD enhanced_VBN shows_NNS a_DT comparison_NN of_IN the_DT DNA_NP cleavage_NN patterns_NNS observed_VBD in_IN the_DT presence_NN of_IN two_CD different_JJ quinolones_NNS ,_, CP-115,953_NP and_CC ciprofloxacin_NP ._SENT Because_IN the_DT GyrAS83W_JJ mutant_NN is_VBZ quinolone_NN resistant_JJ and_CC therefore_RB bound_VBN to_TO give_VB less_JJR cleavage_NN than_IN gyraseWT_NN ,_, we_PP chose_VBD drug_NN concentrations_NNS (_( 100_CD muM_NN )_) that_WDT are_VBP approximately_RB three_CD times_NNS the_DT 50_CD %_NN inhibitory_JJ concentration_NN for_IN supercoiling_VBG (_( data_NNS not_RB shown_VBN )_) ._SENT As_RB for_IN yeast_NN Top2p_NP ,_, the_DT S83W_NP substitution_NN changed_VBD the_DT enzyme_NN cleavage_NN pattern_NN ._SENT Several_JJ cleavage_NN sites_NNS were_VBD reduced_VBN in_IN intensity_NN for_IN GyrAS83W_NNS in_IN the_DT presence_NN of_IN CP-115,953_NP and_CC ciprofloxacin_NN (_( e.g._FW ,_, 2747_CD ,_, 2744_CD ,_, 2772_CD ,_, 2770_CD ,_, 2991_CD ,_, 3020_CD ,_, 3017_CD ,_, and_CC 3020_CD )_) ,_, whereas_IN other_JJ sites_NNS were_VBD enhanced_VBN (_( e.g._FW ,_, 2722_CD ,_, 2893_CD ,_, 2768_CD ,_, 2794_CD ,_, 2805_CD ,_, and_CC 2962_CD )_) ._SENT These_DT results_NNS demonstrate_VBP that_IN the_DT GyrAS83W_JJ mutation_NN markedly_RB affects_VBZ the_DT DNA_NP sequence_NN specificity_NN of_IN DNA_NN gyrase_NN ._SENT FIG._NN 1_CD ._SENT |_SYM CAP_NP homology_NN domain_NN and_CC positions_NNS of_IN Ser740_NP ,_, Gln743_NP ,_, and_CC Thr744_NP in_IN yeast_NN Top2p_NP ._SENT CAP_NN homology_NN domain_NN and_CC positions_NNS of_IN Ser740_NP ,_, Gln743_NP ,_, and_CC Thr744_NP in_IN yeast_NN Top2p_NP ._SENT (_( A_NP )_) Illustration_NN of_IN dimeric_JJ S._NP cerevisiae_NNS topoisomerase_JJ II_NP structure_NN (_( Protein_NP Data_NP Bank_NP accession_NN number_NN )_) ._SENT Drawings_NNS were_VBD generated_VBN using_VBG the_DT program_NN QUANTA_NP (_( version_NN 97_CD )_) ._SENT The_DT helical_JJ ribbon_NN representation_NN shows_VBZ the_DT 92-kDa_NN fragment_NN of_IN the_DT yeast_NN enzyme_NN with_IN a_DT DNA_NP fragment_NN modeled_VBD into_IN each_DT of_IN the_DT putative_JJ DNA-binding_NP sites_NNS ._SENT The_DT CAP_NP homology_NN domain_NN of_IN each_DT protomer_NN is_VBZ highlighted_VBN in_IN green_NN ._SENT (_( B_LS )_) Close_JJ view_NN of_IN the_DT putative_JJ DNA-binding_NP region_NN ,_, presenting_VBG the_DT proposed_VBN proximity_NN of_IN the_DT alpha4-helix_NN within_IN the_DT CAP_NP homology_NN domain_NN ,_, including_VBG Ser_NP 740_CD ,_, Gln_NP 743_CD ,_, and_CC Thr744_NP (_( in_IN a_DT stick_NN model_NN )_) ,_, to_TO DNA_NP ._SENT (_( C_NP )_) Alignment_NN of_IN protein_NN sequence_NN for_IN the_DT yeast_NN (_( Sc_NP Top2p_NP )_) ,_, human_JJ Top2palpha_NP (_( Hu_NP Top2palpha_NP )_) and_CC E._NP coli_NNS gyrase_NN ._SENT The_DT mutated_VBN residues_NNS studied_VBN in_IN the_DT present_JJ report_NN are_VBP indicated_VBN by_IN arrowheads_NNS ._SENT Shaded_JJ residues_NNS correspond_VBP to_TO the_DT alpha4-helix_NN ._SENT No_DT shading_NN is_VBZ shown_VBN for_IN human_JJ Top2p_NP because_IN of_IN lack_NN of_IN structural_JJ data_NNS ._SENT Boxed_VBN regions_NNS indicate_VBP similarity_NN between_IN the_DT amino_NN acid_NN residues_NNS ._SENT Ser763_NN in_IN the_DT human_JJ Top2palpha_NP sequence_NN corresponds_VBZ to_TO Ser740_NP in_IN yeast_NN Top2p_NP ._SENT FIG._NN 2_CD ._SENT |_SYM Comparison_NP of_IN Ca2+-promoted_NP DNA_NP cleavage_NN patterns_NNS of_IN yeast_NN Top2pWT_NP ,_, Top2pS740W_NP ,_, Top2pQ743P_NP ,_, Top2pT744P_NP ,_, and_CC Top2pT744A_NP as_RB well_RB as_IN gyraseWT_NN and_CC GyrAS83W_NN ._SENT Comparison_NN of_IN Ca2+-promoted_NP DNA_NP cleavage_NN patterns_NNS of_IN yeast_NN Top2pWT_NP ,_, Top2pS740W_NP ,_, Top2pQ743P_NP ,_, Top2pT744P_NP ,_, and_CC Top2pT744A_NP as_RB well_RB as_IN gyraseWT_NP and_CC GyrAS83W_NP ._SENT DNA_NP fragments_VBZ from_IN the_DT human_JJ c-myc_NP first_JJ intron_NN (_( A_NP )_) and_CC from_IN the_DT junction_NN between_IN the_DT c-myc_NP first_JJ intron_NN and_CC first_JJ exon_NN (_( B_NP )_) were_VBD prepared_VBN by_IN PCR_NP ._SENT For_IN each_DT fragment_NN ,_, 5'-end-labeling_NP was_VBD performed_VBN with_IN 32P_JJ ._SENT Yeast_NP Top2p_NP reactions_NNS were_VBD performed_VBN at_IN 37C_JJ for_IN 30_CD min_NN (_( A_NP and_CC B_NP )_) ,_, and_CC gyrase_NN reactions_NNS were_VBD performed_VBN at_IN 25C_JJ for_IN 2_CD h_NN (_( C_NP )_) ._SENT In_IN all_DT reactions_NNS ,_, the_DT CaCl2_NP concentration_NN was_VBD 5_CD mM_NNS ._SENT Lanes_NNS :_: Control_NN ,_, without_IN Top2_JJ enzyme_NN ;_: Purine_NP ,_, ladder_NN obtained_VBN after_IN formic_JJ acid_JJ reaction_NN ;_: y_NP WT_NP ,_, yeast_NN wild-type_NN Top2p_NP ;_: y_NP S74_NP 0W_NN ,_, yeast_NN Top2pS740W_NN ;_: y_NP Q743P_NP ,_, yeast_NN Top2pQ743P_NP ;_: y_NP T744P_NP ,_, yeast_NN Top2pT744P_NP ;_: y_NP T744A_NP ,_, yeast_NN Top2pT744A_NP ;_: gyrWT_NP ,_, gyraseWT_NN from_IN E._NP coli_NNS ;_: GyrAS83W_NP ,_, mutant_JJ Ser83Trp_NP gyrase_NN ._SENT Numbers_NNS correspond_VBP to_TO genomic_JJ positions_NNS of_IN the_DT nucleotide_NN covalently_RB linked_VBN to_TO the_DT enzyme_NN via_IN the_DT 5_CD '_POS phosphate_NN ._SENT FIG._NN 3_CD ._SENT |_SYM DNA_NP cleavage_NN patterns_NNS generated_VBN by_IN yeast_NN Top2pWT_NP ,_, Top2pS740W_NP ,_, Top2pQ743P_NP ,_, Top2pT744P_NP ,_, and_CC Top2pT744A_NP enzymes_NNS in_IN the_DT presence_NN of_IN etoposide_NP ,_, the_DT fluoroquinolone_NP CP-115,953_NP ,_, and_CC the_DT intercalator_NN mitoxantrone_NN ._SENT DNA_NP cleavage_NN patterns_NNS generated_VBN by_IN yeast_NN Top2pWT_NP ,_, Top2pS740W_NP ,_, Top2pQ743P_NP ,_, Top2pT744P_NP ,_, and_CC Top2pT744A_NP enzymes_NNS in_IN the_DT presence_NN of_IN etoposide_NP ,_, the_DT fluoroquinolone_NP CP-115,953_NP ,_, and_CC the_DT intercalator_NN mitoxantrone_NN ._SENT DNA_NP fragments_VBZ from_IN the_DT junction_NN between_IN the_DT c-myc_NP first_JJ intron_NN and_CC first_JJ exon_NN between_IN positions_NNS 2671_CD and_CC 3072_CD were_VBD prepared_VBN by_IN PCR_NP using_VBG one_CD primer_NN labeled_VBN with_IN 32P_JJ at_IN the_DT 5_CD '_POS terminus_NN ._SENT The_DT left-hand_JJ panels_NNS show_VBP labeling_VBG of_IN the_DT upper_JJ DNA_NN strand_NN at_IN position_NN 2671_CD ._SENT The_DT right-hand_JJ panels_NNS show_VBP that_IN labeling_VBG of_IN the_DT lower_JJR DNA_NN strand_NN was_VBD at_IN position_NN 3072_CD ._SENT Top2_JJ enzymes_NNS are_VBP indicated_VBN above_IN each_DT lane_NN ._SENT Lanes_NNS :_: y_NP WT_NP ,_, yeast_NN wild-type_NN Top2p_NP ;_: y_NP S740W_NP ,_, yeast_NN Top2pS740W_NN ;_: y_NP Q743P_NP ,_, yeast_NN Top2pQ743P_NP ;_: y_NP T744P_NP ,_, yeast_NN Top2pT744P_NP ;_: y_NP T744A_NP ,_, yeast_NN Top2pT744A_NP ._SENT Concentrations_NNS were_VBD 100_CD muM_NN for_IN etoposide_NP (_( A_NP )_) and_CC CP-115,953_NP (_( B_NP )_) and_CC 1_CD muM_NN for_IN mitoxantrone_NN (_( C_NP )_) ._SENT Reactions_NNS were_VBD performed_VBN at_IN 37C_JJ for_IN 30_CD min_NN in_IN the_DT presence_NN of_IN 5_CD mM_NP MgCl2_NP ._SENT Purine_NN ladders_NNS were_VBD obtained_VBN after_IN formic_JJ acid_JJ reaction_NN ._SENT Numbers_NNS correspond_VBP to_TO genomic_JJ positions_NNS of_IN the_DT nucleotide_NN covalently_RB linked_VBN to_TO Top2p_NP via_IN the_DT 5_CD '_POS phosphate_NN ._SENT Double-headed_JJ arrows_NNS correspond_VBP to_TO DNA_NP cleavage_NN sites_NNS with_IN a_DT 4-bp_JJ stagger_NN that_WDT represent_VBP potential_JJ DNA_NN double-strand_NN breaks_NNS ._SENT In_IN contrast_NN to_TO the_DT mutation_NN causing_VBG Ser740Trp_NP ,_, which_WDT confers_VBZ quinolone_NN resistance_NN ,_, the_DT Thr744Pro_NP substitution_NN causes_VBZ hypersensitivity_NN to_TO CP-115,953_NP ._SENT Figure_NN compares_VBZ DNA_NN cleavage_NN produced_VBN by_IN CP-115,953_NP ,_, ciprofloxacin_NN ,_, and_CC norfloxacin_NN for_IN GyrAWT_NP ,_, Top2pWT_NP ,_, and_CC Top2pT744P_NP ._SENT Remarkably_RB ,_, prominent_JJ cleavage_NN was_VBD observed_VBN for_IN Top2pT744P_NP in_IN the_DT presence_NN of_IN ciprofloxacin_NN and_CC norfloxacin_NN ,_, whose_WP$ antibacterial_NN activities_NNS are_VBP due_JJ to_TO specific_JJ inhibition_NN of_IN bacterial_JJ Top2p_NP and_CC have_VB no_DT effect_NN on_IN mammalian_JJ Top2p_NP ._SENT A_DT number_NN of_IN cleavage_NN sites_NNS stimulated_VBN by_IN Top2pT744P_NP in_IN the_DT presence_NN of_IN quinolones_NNS matched_VBD the_DT E._NP coli_NNS DNA_NN gyrase_NN sites_NNS (_( e.g._FW ,_, at_IN positions_NNS 3202_CD ,_, 3179_CD ,_, 3145_CD ,_, 3121_CD ,_, 3108_CD ,_, 3066_CD ,_, and_CC 3111_CD )_) ._SENT However_RB ,_, other_JJ sites_NNS were_VBD different_JJ for_IN DNA_NN gyrase_NN ._SENT Enhanced_JJ sensitivity_NN to_TO antibacterial_NN quinolones_NNS by_IN the_DT Thr744Pro_NP substitution_NN in_IN yeast_NN Top2p_NP was_VBD also_RB detected_VBN in_IN other_JJ DNA_NN fragments_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT FIG._NN 5_CD ._SENT |_SYM Generation_NP of_IN DNA_NP cleavage_NN by_IN the_DT yeast_NN Top2pT744P_NN mutant_NN in_IN the_DT presence_NN of_IN antibacterial_NN quinolones_NNS ._SENT Generation_NN of_IN DNA_NN cleavage_NN by_IN the_DT yeast_NN Top2pT744P_NN mutant_NN in_IN the_DT presence_NN of_IN antibacterial_NN quinolones_NNS ._SENT A_DT 254-bp_JJ DNA_NN fragment_NN from_IN the_DT c-myc_NP first_JJ intron_NN was_VBD prepared_VBN ._SENT (_( A_NP )_) Labeling_NP of_IN the_DT upper_JJ DNA_NN strand_NN at_IN position_NN 3035_CD ._SENT (_( B_NP )_) Labeling_NP of_IN the_DT lower_JJR DNA_NN strand_NN at_IN position_NN 3288_CD ._SENT Drugs_NNS (_( 100_CD muM_NN each_DT )_) and_CC enzymes_NNS are_VBP indicated_VBN above_IN the_DT lanes_NNS ._SENT Lanes_NNS :_: yWT_NP ,_, yeast_NN wild-type_NN Top2p_NP ;_: Y_NP T744P_NP ,_, Top2pT744P_NP ._SENT Numbers_NNS correspond_VBP to_TO genomic_JJ positions_NNS of_IN the_DT nucleotide_NN covalently_RB linked_VBN to_TO Top_JJ 2p_JJ ._SENT Double-headed_JJ arrows_NNS correspond_VBP to_TO DNA_NP cleavage_NN sites_NNS with_IN a_DT 4-bp_JJ stagger_NN that_WDT represent_VBP potential_JJ DNA_NN double-strand_NN breaks_NNS ._SENT 115,953-stabilized_JJ cleavage_NN complexes_NNS for_IN mutant_JJ Top2T744P_NP enzyme_NN ._SENT :_: Because_IN we_PP observed_VBD that_IN the_DT Thr744Pro_NP substitution_NN enhanced_JJ sensitivity_NN to_TO quinolones_NNS (_( including_VBG the_DT fluoroquinolone_NP CP-115,953_NP )_) and_CC produced_VBN common_JJ DNA_NN cleavage_NN sites_NNS with_IN E._NP coli_NNS DNA_NN gyrase_NN ,_, we_PP examined_VBD whether_IN this_DT particular_JJ amino_NN acid_NN substitution_NN affected_VBD the_DT DNA_NP base_NN preference_NN of_IN yeast_NN Top2p_NN in_IN the_DT presence_NN of_IN CP-115,953_NP ._SENT Cleavage_NN sites_NNS for_IN the_DT three_CD c-myc_NP DNA_NP fragments_NNS and_CC one_CD c-jun_NP fragment_NN (_( see_VB Materials_NNS and_CC Methods_NNS )_) were_VBD analyzed_VBN for_IN both_DT DNA_NN strands_NNS ._SENT For_IN the_DT wild-type_NN yeast_NN Top2p_NP ,_, CP-115,953_NP preferentially_RB stabilized_VBD sites_NNS with_IN C_NP or_CC T_NN at_IN position_NN -1_CD (_( C-1_NP +_SYM T-1_JJ :_: 49_CD out_NN of_IN 65_CD sites_NNS )_) and_CC A_NP or_CC G_NP at_IN position_NN +1_NN (_( A+1_NP +_SYM G+1_JJ :_: 54_CD out_NN of_IN 65_CD sites_NNS )_) ._SENT Complementary_JJ preferences_NNS (_( although_IN slightly_RB weaker_JJR )_) were_VBD seen_VBN for_IN T+4_NP and_CC G+5_NP ._SENT Top2pT744P_NP also_RB demonstrated_VBD a_DT preference_NN for_IN T_NN at_IN position_NN -1_CD ,_, which_WDT was_VBD higher_JJR than_IN that_DT for_IN the_DT wild-type_NN enzyme_NN (_( 41_CD out_RB of_IN 89_CD sites_NNS )_) ,_, in_IN combination_NN with_IN preference_NN for_IN G_NP at_IN position_NN +1_NN (_( 44_CD out_RB of_IN 89_CD sites_NNS )_) ._SENT However_RB ,_, preferences_NNS for_IN C_NP at_IN position_NN -1_CD and_CC A_DT at_IN position_NN +1_NN were_VBD not_RB detectable_JJ in_IN the_DT mutant_JJ protein_NN (_( Thr744Pro_NP )_) ._SENT Moreover_RB ,_, complementary_JJ preference_NN also_RB changed_VBD to_TO A+5_NP ._SENT Because_IN bacterial_JJ Top2_NP enzymes_NNS are_VBP also_RB sensitive_JJ to_TO CP-115,953_NP ,_, we_PP analyzed_VBD the_DT base_NN preferences_NNS for_IN DNA_NN gyrase_NN ._SENT The_DT observed_JJ preferences_NNS for_IN T_NN at_IN position_NN -1_CD (_( 41_CD out_RB of_IN 107_CD sites_NNS )_) and_CC G_NP at_IN position_NN +1_NN (_( 50_CD out_RB of_IN 107_CD sites_NNS )_) are_VBP in_IN agreement_NN with_IN previous_JJ reports_NNS obtained_VBN with_IN the_DT antibacterial_NN fluoroquinolones_NNS ._SENT These_DT data_NNS indicate_VBP that_IN enhanced_JJ quinolone_JJ sensitivity_NN of_IN the_DT mutation_NN causing_VBG Thr744Pro_NP is_VBZ associated_VBN with_IN a_DT shift_NN in_IN base_JJ sequence_NN preferences_NNS ,_, resembling_VBG that_IN of_IN DNA_NN gyrase_NN ._SENT FIG._NN 6_CD ._SENT |_SYM Probability_NN of_IN the_DT observed_JJ base_NN frequency_NN deviations_NNS at_IN Top2p_NP cleavage_NN sites_NNS for_IN the_DT yeast_NN wild-type_NN enzyme_NN ,_, for_IN Top2pT744P_NP and_CC for_IN E._NP coli_NNS Probability_NN of_IN the_DT observed_JJ base_NN frequency_NN deviations_NNS at_IN Top2p_NP cleavage_NN sites_NNS for_IN the_DT yeast_NN wild-type_NN enzyme_NN ,_, for_IN Top2pT744P_NP and_CC for_IN E._NP coli_NNS gyrase_NN in_IN the_DT presence_NN of_IN CP-115,953_NP ._SENT Position_NN 0_CD corresponds_VBZ to_TO the_DT cleavage_NN site_NN ,_, and_CC positions_VBZ -1_CD and_CC +1_JJ to_TO the_DT bases_NNS immediately_IN 3_CD '_'' and_CC 5_CD '_'' from_IN the_DT cleavage_NN site_NN ,_, respectively_RB ._SENT The_DT panels_NNS present_VBP the_DT probability_NN of_IN the_DT observed_JJ base_NN frequency_NN deviations_NNS from_IN expectation_NN for_IN the_DT indicated_JJ enzyme_NN ._SENT On_IN the_DT y_NP axis_NN ,_, P_NN is_VBZ the_DT probability_NN of_IN observing_VBG that_DT deviation_NN or_CC more_JJR ,_, either_CC as_RB excess_JJ (_( above_IN baseline_NN )_) or_CC deficiency_NN (_( below_IN baseline_NN )_) ,_, relative_JJ to_TO the_DT expected_VBN frequency_NN of_IN each_DT individual_JJ base_NN ._SENT Cleavage_NN sites_NNS for_IN the_DT yeast_NN wild-type_NN Top2p_NP (_( A_NP )_) ,_, the_DT yeast_NN Top2pT744P_NP (_( B_NP )_) ,_, and_CC E._NP coli_NNS gyrase_NN (_( C_NP )_) were_VBD analyzed_VBN after_IN treatment_NN with_IN 100_CD muM_NN CP-115,953_NP ._SENT The_DT A_NP '_POS domains_NNS of_IN eukaryotic_JJ Top2_JJ enzymes_NNS (_( homologous_JJ to_TO the_DT amino_NN terminus_NN of_IN the_DT A_NP subunit_NN of_IN gyrase_NN )_) comprise_VBP the_DT primary_JJ DNA_NN binding_VBG sites_NNS and_CC include_VBP the_DT catalytic_JJ tyrosine_NN Y782_NP for_IN the_DT yeast_NN S._NP cerevisiae_NNS ,_, which_WDT is_VBZ homologous_JJ to_TO Y122_NP for_IN E._NP coli_NNS gyrase_NN ._SENT DNA_NP footprinting_NN analyses_NNS indicate_VBP that_IN for_IN eukaryotic_JJ Top2p_NP and_CC bacterial_JJ topoisomerase_NN IV_NP ,_, similar15_NN to_TO 35_CD bp_NN of_IN DNA_NP is_VBZ tightly_RB bound_VBN to_TO the_DT enzyme_NN ._SENT In_IN the_DT case_NN of_IN gyrase_NN ,_, a_DT more_RBR extensive_JJ stretch_NN of_IN DNA_NP (_( similar130_NN bp_NN )_) is_VBZ protected_VBN by_IN the_DT enzyme_NN ._SENT However_RB ,_, the_DT central_JJ section_NN of_IN this_DT region_NN around_IN the_DT DNA_NP cleavage_NN site_NN is_VBZ very_RB similar_JJ in_IN size_NN to_TO that_DT bound_NN by_IN Top2p_NP and_CC topoisomerase_NP IV_NP ._SENT The_DT length_NN of_IN this_DT DNA_NP segment_NN is_VBZ consistent_JJ with_IN the_DT combined_JJ length_NN of_IN the_DT A_NP '_POS grooves_NNS present_JJ in_IN the_DT Top2p_NP and_CC GyrA_NP structures_NNS ._SENT Within_IN the_DT A_NP '_POS domain_NN of_IN Top2p_NP ,_, a_DT 29-kDa_JJ fragment_NN containing_VBG the_DT active-site_NN tyrosine_NN and_CC the_DT helix-turn-helix_NN motif_NN from_IN the_DT CAP_NP homology_NN domain_NN can_MD be_VB cross-linked_VBN to_TO DNA_NN ,_, and_CC protein_NN footprinting_NN suggest_VBP that_IN the_DT binding_NN of_IN DNA_NP protects_VBZ lysines_NNS from_IN chemical_JJ modification_NN within_IN the_DT same_JJ region_NN ._SENT CAP_NN homology_NN domains_NNS contain_VBP typically_RB a_DT three-alpha-helix_NN bundle_NN backed_VBN by_IN beta-sheets_NNS ._SENT Two_CD adjacent_JJ alpha-helices_NNS ,_, usually_RB the_DT second_JJ helix_NN (_( referred_VBN to_TO as_IN alpha3-helix_NN in_IN yeast_NN Top2p_NP according_VBG to_TO reference_NN )and_NN the_DT third_JJ helix_NN (_( referred_VBN to_TO as_IN alpha4-helix_NN of_IN the_DT bundle_NN in_IN yeast_NN Top2p_NP according_VBG to_TO reference_VB )_) ,_, are_VBP connected_VBN by_IN a_DT short_JJ turn_NN ._SENT This_DT motif_NN known_VBN as_IN the_DT helix-turn-helix_NN is_VBZ responsible_JJ for_IN many_JJ of_IN the_DT critical_JJ contacts_NNS between_IN CAP-like_JJ proteins_NNS and_CC DNA_NN ._SENT The_DT second_JJ helix_NN of_IN this_DT motif_NN generally_RB inserts_VBZ into_IN the_DT major_JJ groove_NN of_IN DNA_NN with_IN the_DT turn_NN contacting_VBG the_DT phosphodiester_NN backbone_NN ._SENT Our_PP$ observations_NNS suggest_VBP that_IN specific_JJ substitutions_NNS in_IN the_DT alpha4-helix_NN (_( Thr744Pro_NP ,_, Gln743Pro_NP ,_, and_CC Ser740Trp_NP of_IN eukaryotic_NP Top2p_NP )_) ,_, which_WDT corresponds_VBZ to_TO the_DT third_JJ helix_NN of_IN the_DT CAP_NP homology_NN domain_NN ,_, can_MD change_VB the_DT enzyme-DNA_NN interactions_NNS ,_, as_RB reflected_VBN by_IN differences_NNS in_IN DNA_NN cleavage_NN patterns_NNS induced_VBN in_IN the_DT presence_NN of_IN Ca2+_NP or_CC in_IN the_DT presence_NN of_IN intercalating_VBG and_CC nonintercalating_VBG drugs_NNS ._SENT We_PP also_RB observed_VBD differences_NNS in_IN base_JJ sequence_NN preferences_NNS ._SENT We_PP interpret_VBP these_DT results_NNS as_IN an_DT indication_NN that_IN the_DT alpha4-helix_NN of_IN the_DT Top2p_NP CAP_NP homology_NN domain_NN is_VBZ critical_JJ for_IN DNA_NP sequence_NN recognition_NN prior_RB to_TO cleavage_NN of_IN the_DT G_NP strand_NN ,_, which_WDT is_VBZ consistent_JJ with_IN the_DT proposed_VBN binding_NN of_IN DNA_NN to_TO yeast_NN Top2p_NN with_IN the_DT alpha4-helix_NN close_NN to_TO the_DT catalytic_JJ tyrosine_NN and_CC to_TO the_DT ends_NNS of_IN the_DT cleaved_VBN DNA_NN ._SENT Figure_NN presents_VBZ the_DT positions_NNS of_IN Ser740_NP ,_, Gln743_NP ,_, and_CC Thr744_NP in_IN the_DT yeast_NN Top2_JJ protein_NN ._SENT These_DT conserved_VBN residues_NNS tend_VBP to_TO be_VB buried_VBN inside_IN the_DT protein_NN ,_, while_IN the_DT nonconserved_JJ residues_NNS Ser740_NP and_CC Gln743_NP are_VBP more_RBR solvent_JJ accessible_JJ ._SENT The_DT nonconserved_JJ amino_NN acid_NN residues_NNS might_MD contribute_VB to_TO the_DT observed_JJ differences_NNS in_IN DNA_NP sequence_NN selectivity_NN and_CC drug_NN sensitivity_NN between_IN the_DT bacterial_JJ ,_, the_DT yeast_NN ,_, and_CC the_DT human_JJ Top2_JJ enzymes_NNS ._SENT Other_JJ regions_NNS of_IN Top2p_NP must_MD interact_VB with_IN different_JJ DNA_NN segments_NNS ,_, such_JJ as_IN the_DT T_NN segment_NN for_IN the_DT strand_NN passage_NN reaction_NN ._SENT The_DT B_NP '_POS domain_NN (_( homologous_JJ to_TO B_NP subunit_NN of_IN gyrase_NN )_) is_VBZ also_RB essential_JJ for_IN DNA_NN binding_NN and_CC cleavage_NN ._SENT Recently_RB it_PP was_VBD proposed_VBN that_IN DNA_NN breakage_NN and_CC rejoining_VBG by_IN Top2p_NP involve_VBP the_DT coordinated_VBN action_NN of_IN the_DT CAP_NP homology_NN domain_NN in_IN the_DT A_NP '_POS fragment_NN containing_VBG the_DT active-site_NN tyrosine_NN together_RB with_IN the_DT Rossmann_NP fold_NN in_IN the_DT B_NP '_POS fragment_NN (_( ,_, ,_, ;_: J._NP G._NP Heddle_NP ,_, and_CC A._NP Maxwell_NP ,_, submitted_VBN for_IN publication_NN )_) ._SENT The_DT Rossmann_NP fold_NN ,_, which_WDT is_VBZ important_JJ for_IN DNA_NN binding_NN and_CC cleavage_NN reactions_NNS ,_, contains_VBZ a_DT number_NN of_IN highly_RB conserved_VBN acidic_JJ residues_NNS that_WDT probably_RB bind_VBP divalent_JJ metals_NNS ._SENT Structural_JJ and_CC biochemical_JJ studies_NNS suggest_VBP that_IN the_DT active-site_JJ tyrosine_NN in_IN the_DT DNA-binding_NP domain_NN of_IN one_CD protomer_NN cooperates_VBZ with_IN several_JJ residues_NNS in_IN the_DT Rossmann_NP fold_NN of_IN the_DT other_JJ protomer_NN ._SENT Our_PP$ data_NNS suggest_VBP that_IN not_RB only_RB the_DT active-site_NN tyrosine_NN and_CC the_DT Rossmann_NP fold_NN domain_NN but_CC also_RB the_DT alpha4-helix_NN of_IN the_DT CAP_NP domain_NN are_VBP involved_VBN in_IN the_DT concerted_JJ molecular_JJ actions_NNS ,_, including_VBG DNA_NP interactions_NNS leading_VBG to_TO sequence-specific_JJ cleavage_NN of_IN the_DT G-strand_NP duplex_NN DNA_NN ._SENT We_PP have_VBP shown_VBN that_IN the_DT Ca2+-_NP and_CC drug-generated_JJ DNA_NN cleavage_NN patterns_NNS of_IN Top2pT744P_NP and_CC Top2p_NP Q743P_NP are_VBP different_JJ from_IN those_DT of_IN Top2pT744A_NP and_CC Top2pWT_NP and_CC that_IN Top2pT744A_NP is_VBZ comparable_JJ to_TO Top2pWT_NP ._SENT Since_IN the_DT Top2p_NP Q743P_NP substitution_NN does_VBZ not_RB lead_VB to_TO enhanced_JJ drug_NN sensitivity_NN ,_, the_DT change_NN in_IN the_DT observed_JJ pattern_NN of_IN Top2p_NP cleavage_NN sites_NNS cannot_MD arise_VB solely_RB from_IN global_JJ quantitative_JJ alterations_NNS ._SENT Also_RB ,_, since_IN Top2pT744A_NP does_VBZ not_RB have_VB a_DT pattern_NN of_IN cleavage_NN that_WDT differs_VBZ from_IN the_DT wild-type_NN enzyme_NN ,_, Thr744_NP probably_RB does_VBZ not_RB play_VB a_DT crucial_JJ role_NN in_IN determining_VBG cleavage_NN site_NN selection_NN by_IN the_DT enzyme_NN ._SENT Since_IN detailed_JJ structural_JJ data_NNS for_IN any_DT of_IN the_DT mutant_JJ proteins_NNS are_VBP not_RB yet_RB available_JJ ,_, we_PP modeled_VBD the_DT specific_JJ molecular_JJ changes_NNS that_WDT might_MD result_VB from_IN the_DT Thr744Ala/Pro_NP and_CC Gln743Pro_NP substitutions_NNS in_IN the_DT yeast_NN Top2p_NN structure_NN ._SENT Molecular_JJ dynamics_NNS simulations_NNS of_IN the_DT Thr744Pro_NP mutant_NN Top2p_NP predicted_VBD structural_JJ changes_NNS within_IN the_DT CAP_NP homology_NN domain_NN (_( data_NNS not_RB shown_VBN ;_: see_VBP also_RB reference_VB )_) ._SENT Compared_VBN to_TO wild-type_VB Top2p_NP and_CC Top2pT744A_NP ,_, the_DT Thr744Pro_NP substitution_NN was_VBD associated_VBN with_IN a_DT kink_NN in_IN the_DT alpha4-helix_NN and_CC a_DT bending_VBG angle_NN of_IN approximately_RB 37o_JJ ._SENT The_DT helical_JJ structure_NN was_VBD preserved_VBN on_IN both_DT sides_NNS of_IN the_DT kink_NN (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT simulations_NNS suggest_VBP that_IN an_DT alteration_NN in_IN the_DT secondary_JJ structure_NN of_IN the_DT alpha4-helix_NN can_MD alter_VB protein-DNA_NN interactions_NNS ._SENT It_PP is_VBZ important_JJ to_TO note_VB ,_, however_RB ,_, that_IN changes_NNS in_IN other_JJ parts_NNS of_IN the_DT protein_NN also_RB occurred_VBD ._SENT Therefore_RB ,_, it_PP is_VBZ premature_JJ to_TO conclude_VB that_IN all_DT of_IN the_DT biochemical_JJ alterations_NNS we_PP observed_VBD in_IN the_DT mutant_JJ proteins_NNS arise_VBP solely_RB from_IN changes_NNS in_IN the_DT alpha4-helix_NN ._SENT A_DT key_JJ issue_NN in_IN understanding_VBG the_DT mechanism_NN of_IN action_NN of_IN Top2p_NP targeting_VBG drugs_NNS is_VBZ the_DT determination_NN of_IN where_WRB the_DT drugs_NNS bind_NN in_IN the_DT Top2p/DNA_NP complex_NN ._SENT Our_PP$ present_JJ findings_NNS indicate_VBP that_IN the_DT same_JJ Top2p_NP domain_NN that_WDT presumably_RB interacts_VBZ with_IN DNA_NN is_VBZ also_RB critical_JJ for_IN drug_NN interaction_NN in_IN the_DT Top2p/DNA/drug_NP ternary_JJ complex_NN ._SENT In_IN particular_JJ ,_, the_DT solvent-exposed_JJ residues_NNS Ser740_NP ,_, Gln743_NP ,_, and_CC to_TO a_DT lesser_JJR extent_NN Thr744_NP ,_, which_WDT affect_VBP drug_NN activity_NN ,_, are_VBP important_JJ ,_, directly_RB or_CC indirectly_RB ,_, for_IN drug_NN binding_VBG to_TO the_DT Top2p/DNA_NP complex_NN ._SENT An_DT intriguing_JJ finding_NN arising_VBG from_IN this_DT work_NN is_VBZ that_IN a_DT quinolone-hypersensitive_JJ yeast_NN Top2p_NP mutant_NN ,_, resulting_VBG in_IN Thr744Pro_NP substitution_NN ,_, changed_VBD the_DT DNA_NP cleavage_NN pattern_NN in_IN the_DT presence_NN of_IN quinolones_NNS so_RB that_IN it_PP more_RBR closely_RB resembled_VBN the_DT DNA_NP cleavage_NN pattern_NN of_IN a_DT quinolone-sensitive_JJ prokaryotic_JJ topoisomerase_NN II_NP ._SENT Quinolones_NNS act_VBP against_IN eukaryotic_JJ topoisomerase_NN II_NP by_IN accelerating_VBG the_DT rate_NN of_IN DNA_NN cleavage_NN ._SENT Recent_JJ studies_NNS have_VBP shown_VBN that_IN along_RB with_IN gyrase_NN and_CC topoisomerase_NN IV_NP of_IN E._NP coli_NNS ,_, quinolones_NNS can_MD also_RB inhibit_VB religation_NN ._SENT A_DT plausible_JJ model_NN is_VBZ that_IN the_DT quinolone-hypersensitive_JJ mutant_NN allows_VBZ quinolones_NNS to_TO inhibit_VB religation_NN as_IN well_RB ._SENT By_IN this_DT hypothesis_NN ,_, the_DT action_NN of_IN quinolones_NNS against_IN Top2pThr744Pro_NP more_RBR closely_RB resembles_VBZ the_DT action_NN of_IN quinolones_NNS against_IN prokaryotic_JJ topoisomerase_NN II_NP ,_, demonstrating_VBG conservation_NN of_IN mechanisms_NNS of_IN drug_NN action_NN between_IN eukaryotic_JJ and_CC prokaryotic_JJ type_NN II_NP topoisomerases_NNS ._SENT Thus_RB ,_, the_DT quinolone-protein_NN interaction_NN domains_NNS between_IN the_DT prokaryotic_JJ and_CC eukaryotic_JJ enzymes_NNS may_MD be_VB comparable_JJ ,_, with_IN only_RB limited_VBN differences_NNS preventing_VBG antibacterial_NN quinolones_NNS from_IN acting_VBG against_IN eukaryotic_JJ Top2p_NP ._SENT null_JJ labeled_VBN DNA_NN fragments_NNS by_IN PCR_NP ._SENT :_: Three_CD sets_NNS of_IN labeled_VBN DNA_NN fragments_NNS were_VBD prepared_VBN from_IN the_DT human_JJ c-myc_NN gene_NN by_IN PCR_NP ._SENT A_DT 254-bp_JJ DNA_NN fragment_NN from_IN the_DT first_JJ intron_NN was_VBD prepared_VBN between_IN positions_NNS 3035_CD and_CC 3288_CD (_( GenBank_NP accession_NN )_) using_VBG the_DT following_VBG oligonucleotides_NNS :_: 5'-GTAATCCAGAACTGGATCGG-3_JJ '_'' for_IN the_DT upper_JJ strand_NN and_CC 5'-ATGCGGTCCCTACTCCAAGG-3_JJ '_'' for_IN the_DT lower_JJR strand_NN (_( annealing_VBG temperature_NN ,_, 56C_NP )_) ._SENT A_DT 401-bp_JJ DNA_NN fragment_NN from_IN the_DT junction_NN between_IN the_DT first_JJ intron_NN and_CC the_DT first_JJ exon_NN was_VBD prepared_VBN between_IN positions_NNS 2671_CD and_CC 3072_CD using_VBG the_DT following_VBG oligonucleotides_NNS :_: 5'-TGCCGCATCCACGAAACTTT-3_JJ '_'' for_IN the_DT upper_JJ strand_NN and_CC 5'-TTGACAAGTCACTTTACCCC-3_JJ '_'' for_IN the_DT lower_JJR strand_NN (_( annealing_VBG temperature_NN ,_, 60C_JJ )_) ._SENT A_DT 480-bp_JJ fragment_NN from_IN the_DT first_JJ exon_NN containing_VBG promoters_NNS P1and_NP P2_NP was_VBD prepared_VBN between_IN positions_NNS 2265_CD and_CC 2745_CD using_VBG the_DT following_VBG oligonucleotides_NNS :_: 5'-GATCCTCTCTCGCTAATCTCCGCCC-3_JJ '_'' for_IN the_DT upper_JJ strand_NN and_CC 5'-TCCTTGCTCGGGTGTTGTAAGTTCC-3_JJ '_'' for_IN the_DT lower_JJR strand_NN (_( annealing_VBG temperature_NN ,_, 70C_NP )_) ._SENT A_DT 213-bp_JJ fragment_NN from_IN the_DT human_JJ c-jun_NP gene_NN was_VBD prepared_VBN between_IN positions_NNS 5'-TGTTGACAGCGGCGGAAAGCAGS-3_NN '_'' for_IN the_DT upper_JJ strand_NN and_CC 5'-CGTCCTTCTTCTCTTGCGTGGCTCT-3_JJ '_'' for_IN the_DT lower_JJR strand_NN (_( annealing_VBG temperature_NN ,_, 64C_JJ )_) ._SENT Single-end_NN labeling_VBG of_IN these_DT DNA_NP fragments_NNS was_VBD obtained_VBN by_IN 5'-end_NN labeling_VBG of_IN the_DT specific_JJ primer_NN oligonucleotide_NN ._SENT Ten_CD picomoles_NNS of_IN DNA_NP was_VBD incubated_VBN for_IN 60_CD min_NN at_IN 37C_JJ with_IN 10_CD U_NN of_IN T4_NP polynucleotide_NN kinase_NN and_CC 10_CD pM_NN [_SYM gamma-32P]ATP_NN (_( 100_CD muCi_NNS )_) in_IN kinase_NN buffer_NN (_( 70_CD mM_NP Tris-HCl_NP ,_, pH_NN 7.6_CD ;_: 0.1_CD M_NP KCl_NP ;_: 10_CD mM_NP MgCl2_NP ;_: 5_CD mM_NN dithiothreitol_NN ;_: bovine_JJ serum_NN albumin_NN [_SYM 0.5_CD mg/ml_NN ]_SYM )_) ._SENT Reactions_NNS were_VBD stopped_VBN by_IN heat_NN denaturation_NN at_IN 70C_NP for_IN 15_CD min_NN ._SENT After_IN purification_NN using_VBG Sephadex_NP G-25_NP columns_NNS (_( Boehringer_NP Mannheim_NP )_) ,_, the_DT labeled_VBN oligonucleotides_NNS were_VBD used_VBN for_IN PCR_NP ._SENT Approximately_RB 0.1_CD mug_NN of_IN the_DT c-myc_NP DNA_NN that_WDT had_VBD been_VBN restricted_VBN by_IN SmaI_NP and_CC PvuII_NP (_( fragment_VB spanning_VBG positions_NNS 2265_CD to_TO 2745_CD )_) and_CC XhoI_NP and_CC XbaI_NP (_( fragment_VB spanning_VBG positions_NNS 2671_CD to_TO 3072_CD and_CC fragment_VB 3035_CD to_TO 3288_CD )_) was_VBD used_VBN as_IN a_DT template_NN for_IN the_DT PCR_NP ._SENT Ten_CD picomoles_NNS of_IN each_DT oligonucleotide_NN primer_NN ,_, one_CD of_IN them_PP being_VBG 5_CD '_POS labeled_VBN ,_, was_VBD used_VBN in_IN 22_CD temperature_NN cycle_NN reactions_NNS (_( each_DT cycle_NN with_IN 94C_NN for_IN 1_CD min_NN ,_, annealing_VBG for_IN 1_CD min_NN ,_, and_CC 72C_NP for_IN 2_CD min_NN )_) ._SENT The_DT last_JJ extension_NN was_VBD for_IN 10_CD min_NN ,_, and_CC DNA_NP was_VBD purified_VBN using_VBG PCR_NP Select-II_NP columns_NNS (_( 5Prime-3Prime_NP Inc._NP ,_, Boulder_NP ,_, Colo._NP )_) ._SENT Wild-type_NP yeast_NN Top2p_NP ,_, Ser740Trp_NP ,_, Gln743Pro_NP ,_, Thr744Pro_NP ,_, and_CC Thr744Ala_NP proteins_NNS were_VBD overexpressed_VBN using_VBG YEpTOP2-PGAL1_NP or_CC YEptop2-S*W-PGAL1_NP and_CC yeast_NN strain_NN JEL1t1-_NP and_CC purified_VBN to_TO homogeneity_NN as_RB previously_RB described_VBD (_( 59_CD )_) ._SENT The_DT detailed_JJ procedure_NN has_VBZ been_VBN described_VBN elsewhere_RB ._SENT GyrA_NP (_( gift_NN of_IN N._NP A._NP Gormley_NP )_) ,_, GyrAS83W_NP (_( gift_NN of_IN C._NP J._NP R._NP Willmott_NP )_) ,_, and_CC GyrB_NP were_VBD purified_VBN as_IN described_VBN previously_RB ._SENT GyrAS83W_NNS was_VBD shown_VBN to_TO have_VB the_DT expected_VBN level_NN of_IN quinolone-resistant_JJ supercoiling_NN activity_NN when_WRB complexed_VBN with_IN wild-type_NN gyrB_NN ._SENT generated_VBN DNA_NN cleavage_NN reactions_NNS ._SENT :_: For_IN the_DT yeast_NN Top2p_NN experiments_NNS ,_, DNA_NN fragments_NNS (_( 5_CD x_SYM 104_CD to_TO 10_CD x_SYM 104_CD dpm/reaction_NN )_) were_VBD equilibrated_VBN with_IN drug_NN or_CC with_IN the_DT corresponding_JJ 1_CD %_NN dimethyl_NN sulfoxide_NN concentration_NN in_IN 10_CD mM_NP Tris-HCl_NP (_( pH_NN 7.5)-50_NP mM_NP KCl-5_NP mM_NP MgCl2-2_NP mM_NP dithiothreitol-0.1_JJ mM_NP Na2EDTA-1_NP mM_NP ATP-bovine_NP serum_NN albumin_NN (_( 15_CD mug/ml_NN )_) for_IN 5_CD min_NN before_IN the_DT addition_NN of_IN 8_CD U_NN (_( 80_CD ng_NNS )_) of_IN purified_VBN Top2p_NN in_IN a_DT 10-mul_NP final_JJ reaction_NN volume_NN ._SENT Unless_IN otherwise_RB indicated_VBN ,_, reactions_NNS were_VBD for_IN 30_CD min_NN at_IN 37C_JJ ._SENT Reactions_NNS were_VBD stopped_VBN by_IN adding_VBG EDTA_NP and_CC sodium_NN dodecyl_NN sulfate_NN (_( 25_CD mM_NP and_CC 1_CD %_NN final_JJ concentrations_NNS ,_, respectively_RB )_) and_CC were_VBD further_RBR digested_VBN with_IN proteinase_NN K_NP (_( 0.4-mg/ml_JJ final_JJ concentration_NN for_IN 30_CD min_NN at_IN 55C_NN )_) ._SENT For_IN the_DT DNA_NP gyrase_NN experiments_NNS ,_, similar_JJ conditions_NNS were_VBD used_VBN except_IN that_IN the_DT DNA_NP cleavage_NN reactions_NNS were_VBD performed_VBN with_IN 10_CD to_TO 15_CD U_NN of_IN purified_VBN E._NP coli_NNS gyrase_NN for_IN 120_CD min_NN at_IN 25C_JJ ._SENT For_IN DNA_NP sequence_NN analysis_NN ,_, samples_NNS were_VBD precipitated_VBN with_IN ethanol_NN and_CC resuspended_JJ in_IN 5_CD mul_NN of_IN loading_VBG buffer_NN (_( 80_CD %_NN formamide_NN ,_, 10_CD mM_NP NaOH_NP ,_, 1_CD mM_NP EDTA_NP ,_, 0,1_CD %_NN xylene_NN cyanol_NN ,_, 0.1_CD %_NN bromphenol_NN blue_NN )_) ._SENT Samples_NNS were_VBD heated_VBN to_TO 95C_NN for_IN 5_CD min_NN and_CC thereafter_RB loaded_VBN onto_IN DNA_NP sequencing_NP gels_NNS (_( 7_CD %_NN polyacrylamide_NN ;_: 19:1_CD acrylamide-bisacrylamide_NN )_) containing_VBG 7_CD M_NN urea_NN in_IN 1x_NP Tris-borate-EDTA_NP buffer_NN ._SENT Electrophoresis_NN was_VBD performed_VBN at_IN 2,500_CD V_CD (_( 60_CD W_NN )_) for_IN 2_CD to_TO 3_CD h._NN The_DT gels_NNS were_VBD dried_VBN on_IN Whatman_NP no_RB ._SENT 3MM_JJ paper_NN sheets_NNS and_CC visualized_VBD using_VBG a_DT PhosphorImager_NP (_( Molecular_NP Dynamics_NP ,_, Sunnyvale_NP ,_, Calif._NP )_) and_CC ImageQuant_NP software_NN ._SENT The_DT determination_NN of_IN preferred_JJ bases_NNS around_IN Top2p_NP cleavage_NN sites_NNS was_VBD done_VBN as_IN described_VBN previously_RB ._SENT Modeling_VBG of_IN the_DT Thr744Pro_NP substitution_NN into_IN published_VBN crystal_NN structure_NN data_NNS of_IN a_DT 92-kDa_NN fragment_NN of_IN yeast_NN Top2p_NP (_( PDB_NP identification_NN code_NN 1bgw_NN )_) was_VBD performed_VBN with_IN the_DT molecular_JJ modeling_NN package_NN QUANTA_NP (_( version_NN 96_CD )_) run_NN on_IN both_CC an_DT SGI_NP Crimson_NP and_CC an_DT SGI_NP Octane_NP workstation_NN ._SENT Energy_NN calculations_NNS and_CC related_JJ operations_NNS ,_, such_JJ as_IN energy_NN minimizations_NNS and_CC the_DT molecular_JJ dynamics_NN simulations_NNS ,_, were_VBD carried_VBN out_RP with_IN QUANTA_NP 's_POS associated_JJ molecular_JJ mechanics_NNS program_NN CHARMm_NP ,_, version_NN 23.1_CD ,_, run_VBN on_IN a_DT separate_JJ computation_NN host_NN ,_, a_DT Digital_NP 2100_CD AlphaServer_NP 4/275_CD ,_, using_VBG the_DT MSI_NP parameter_NN set_VBD version_NN 22.0_CD ._SENT In_IN order_NN to_TO generate_VB a_DT low-energy_NN starting_VBG geometry_NN for_IN the_DT subsequent_JJ molecular_JJ dynamics_NNS simulation_NN ,_, each_DT of_IN the_DT wild-type_NN and_CC mutant_JJ structures_NNS was_VBD energy_NN minimized_VBN in_IN 5,000_CD steps_NNS of_IN Adopted-Basis_NP Newton-Raphson_JJ minimization_NN ._SENT Each_DT of_IN these_DT minimized_VBN structures_NNS was_VBD subjected_VBN to_TO a_DT total_NN of_IN 300_CD ps_NNS of_IN molecular_JJ dynamics_NNS simulation_NN using_VBG the_DT Verlet_NP algorithm_NN for_IN integration_NN of_IN the_DT equations_NNS of_IN motion_NN ._SENT Using_VBG a_DT step_NN size_NN of_IN 1_CD fs_NNS ,_, the_DT structures_NNS were_VBD heated_VBN from_IN 0_CD to_TO 310_CD K_NN in_IN approximately_RB 10_CD ps_NNS (_( 9,982_CD steps_NNS )_) ,_, then_RB equilibrated_VBN at_IN 310_CD K_NN for_IN 40_CD ps_NNS (_( 40,000_CD steps_NNS )_) with_IN an_DT equilibration_NN frequency_NN of_IN 200_CD steps_NNS ,_, and_CC finally_RB subjected_VBN to_TO a_DT simulation_NN at_IN 310_CD K_NN for_IN 250_CD ps_NNS (_( 250,000_CD steps_NNS )_) ._SENT Snapshot_NN frames_NNS containing_VBG the_DT current_JJ coordinates_NNS were_VBD written_VBN out_IN every_DT 50_CD steps_NNS ._SENT Alteration_NN of_IN Ca2+-promoted_NP DNA_NP cleavage_NN by_IN Ser740Trp_NP ,_, Gln743Pro_NP ,_, Thr744Pro_NP ,_, and_CC Thr744Ala_NP substitutions_NNS in_IN yeast_NN Top2p_NP and_CC by_IN the_DT Ser83Trp_NP substitution_NN in_IN bacterial_JJ GyrA_NP ._SENT |_SYM It_PP is_VBZ well_RB known_VBN that_IN DNA_NN cleavage_NN by_IN type_NN II_NP DNA_NP topoisomerases_NNS can_MD be_VB stimulated_VBN by_IN a_DT variety_NN of_IN drugs_NNS ,_, but_CC cleavage_NN can_MD also_RB be_VB stimulated_VBN when_WRB Ca2+_NP is_VBZ substituted_VBN for_IN Mg2+_NP in_IN the_DT enzyme_NN reaction_NN ._SENT In_IN this_DT case_NN it_PP is_VBZ likely_JJ that_IN the_DT cleavage_NN specificity_NN reflects_VBZ the_DT natural_JJ sequence_NN specificity_NN of_IN the_DT enzyme_NN ._SENT The_DT Ca2+-promoted_JJ ,_, drug-independent_JJ DNA_NP cleavage_NN sites_NNS generated_VBN by_IN yeast_NN wild-type_NN Top2p_NP (_( Top2pWT_NP )_) and_CC four_CD yeast_NN mutant_JJ proteins_NNS (_( Top2pS740W_NP ,_, Top2pQ743P_NP ,_, Top2pT744P_NP ,_, and_CC Top2pT744A_NP )_) were_VBD mapped_VBN in_IN two_CD different_JJ c-myc_NP DNA_NP fragments_VBZ ._SENT Figure_NN To_TO further_RBR investigate_VB differences_NNS between_IN Top2pS740W_NP ,_, Top2pQ743P_NP ,_, Top2pT744P_NP ,_, Top2pT744A_NP ,_, and_CC Top2pWT_NP ,_, we_PP compared_VBD drug-stimulated_JJ DNA_NN cleavage_NN patterns_NNS ._SENT Etoposide_NP results_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT Results_NNS for_IN the_DT fluoroquinolone_JJ CP-115,953_NN in_IN are_VBP shown_VBN in_IN Fig._NN ,_, and_CC those_DT for_IN mitoxantrone_NN are_VBP shown_VBN in_IN Fig._NN ._SENT Top2pS740W_NP (_( as_RB well_RB as_IN the_DT corresponding_JJ yeast_NN mutant_NN )_) has_VBZ been_VBN previously_RB characterized_VBN as_IN being_VBG resistant_JJ to_TO the_DT fluoroquinolone_NP CP-115,953_NP and_CC hypersensitive_JJ to_TO etoposide_NP ._SENT Compared_VBN with_IN Top2pWT_NP and_CC the_DT other_JJ mutant_JJ proteins_NNS ,_, several_JJ cleavage_NN sites_NNS stimulated_VBN by_IN etoposide_NP were_VBD markedly_RB enhanced_VBN with_IN Top2pS740W_NN ,_, e.g._FW ,_, at_IN positions_NNS 2711_CD to_TO 2712_CD ,_, 2781_CD ,_, 2983_CD ,_, 3011_CD ,_, 3019_CD ,_, and_CC 3026_CD ._SENT Proline_NN substitutions_NNS at_IN positions_NNS 744_CD and_CC 743_CD also_RB changed_VBN the_DT distribution_NN of_IN Top2p-mediated_JJ DNA_NN cleavages_NNS ._SENT These_DT effects_NNS were_VBD more_RBR pronounced_VBN for_IN Top2pT744P_NP than_IN for_IN Top2pQ743P_NP ._SENT By_IN contrast_NN ,_, Top2pT744A_NP behaved_VBD very_RB similarly_RB to_TO Top2pWT_NP ._SENT Together_RB ,_, the_DT data_NNS shown_VBN in_IN Fig._NN demonstrate_VBP that_IN single_JJ mutations_NNS in_IN the_DT alpha4-helix_NN of_IN Top2p_NP (_( Ser740Trp_NP ,_, Gln743Pro_NP ,_, and_CC Thr744Pro_NP )_) changed_VBD enzyme-specific_JJ DNA_NN cleavage_NN patterns_NNS produced_VBN by_IN nonintercalating_VBG and_CC intercalating_VBG drugs_NNS ._SENT generated_VBN DNA_NN cleavage_NN patterns_NNS by_IN the_DT mutant_JJ GyrAS83W_NN and_CC wild-type_NN DNA_NN gyrase_NN ._SENT :_: We_PP next_RB tested_VBD the_DT role_NN of_IN the_DT corresponding_JJ alpha4-helix_NN in_IN the_DT bacterial_JJ topoisomerase_NN II_NP ,_, DNA_NN gyrase_NN ._SENT Figure_NN FIG._NN 4_CD ._SENT |_SYM DNA_NP cleavage_NN patterns_NNS generated_VBN by_IN gyraseWT_NN and_CC mutant_JJ GyrAS83W_NNS in_IN the_DT presence_NN of_IN the_DT quinolones_NNS CP-115,953_NP and_CC ciprofloxacin_NP ._SENT DNA_NP cleavage_NN patterns_NNS generated_VBN by_IN gyraseWT_NN and_CC mutant_JJ GyrAS83W_NNS in_IN the_DT presence_NN of_IN the_DT quinolones_NNS CP-115,953_NP and_CC ciprofloxacin_NP ._SENT The_DT same_JJ DNA_NN fragments_NNS presented_VBN in_IN Fig._NN were_VBD used_VBN ._SENT The_DT left-hand_JJ panel_NN shows_NNS labeling_VBG of_IN the_DT upper_JJ DNA_NN strand_NN ;_: the_DT right-hand_JJ panel_NN shows_NNS labeling_VBG of_IN the_DT lower_JJR DNA_NN strand_NN ._SENT Drugs_NNS and_CC enzymes_NNS are_VBP indicated_VBN above_IN each_DT lane_NN ._SENT Concentrations_NNS were_VBD 100_CD muM_NN for_IN CP-115,953_NP and_CC ciprofloxacin_NP ,_, respectively_RB ._SENT Cleavage_NN reactions_NNS were_VBD performed_VBN at_IN 25C_JJ for_IN 2_CD h_NN in_IN the_DT presence_NN of_IN 5_CD mM_NP MgCl2_NP ._SENT Purine_NN ladders_NNS were_VBD obtained_VBN after_IN formic_JJ acid_JJ reaction_NN ._SENT Lanes_NNS :_: Control_NP ,_, no_DT Top2p_NP ,_, no_DT drug_NN treatment_NN ;_: Gyr_NP WT_NP :_: gyraseWT_NN from_IN E._NP coli_NNS ;_: GyrAS83W_NP ,_, mutant_JJ Ser83Trp_NP gyrase_NN ._SENT Numbers_NNS correspond_VBP to_TO genomic_JJ positions_NNS of_IN the_DT nucleotide_NN covalently_RB linked_VBN to_TO Top2p_NP ._SENT Double-headed_JJ arrows_NNS correspond_VBP to_TO DNA_NP cleavage_NN sites_NNS with_IN a_DT 4-bp_JJ stagger_NN that_WDT represent_VBP potential_JJ DNA_NN double-strand_NN breaks_NNS ._SENT 